+86-28-82633987
Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃
115.0600
2.3375
.6666
.0986
3.5989
3.5956
Low
88.7319
2.5425
Yes
No
No
No
Yes
Yes
1.8
Yes
No
Yes
No
3-Hydroxymorindone, CAS number 80368-74-7, is a typical anthraquinone natural product, widely found in Rubiaceae plants, especially in Morinda species. As a natural pigment, 3-hydroxybaquinone not only plays an important physiological role in plants, but also, due to its unique chemical structure and biological activity, has attracted widespread attention in pharmacology in recent years. Its potential application value in anti-osteoporosis and other diseases has become a research hotspot. Osteoporosis is a metabolic bone disease characterized by reduced bone mass and microstructure destruction of bone tissue, severely affecting the quality of life and healthy lifespan of the elderly. Traditional treatments have certain side effects and resistance issues, but natural products, due to their multi-target regulation and relatively low toxicity and side effects, have become an important source for developing new anti-osteoporosis drugs.
This paper will systematically review the chemical structure and physicochemical properties, plant origin, and extraction methods of 3-hydroxy-bathoquinone, delve into its pharmacological activity and mechanism of action, focus on analyzing its molecular targets and signaling pathway regulation in anti-osteoporosis treatment, and, combined with druggability parameters and pharmacokinetic characteristics, evaluate its clinical application prospects, aiming to provide theoretical basis and scientific guidance for subsequent drug development and clinical research.
3-Hydroxy-Bathoquinone belongs to the anthraquinone class of compounds, with a molecular formula C15H10O6 and a molecular weight of 286.2390. Its basic framework is an anthraquinone ring, with multiple hydroxyl functional groups in its structure. The presence of three hydroxyl groups gives it strong hydrophilicity and biological activity. Its chemical structure features include two aromatic rings connected by a quinone structure, with the hydroxyl group on the quinone ring participating in hydrogen bond formation, affecting its solubility and ability to bind to biological macromolecules.
In terms of physicochemical properties, the LogP value of 3-hydroxy-baterinone is 2.3375, indicating moderate lipid solubility, which is beneficial for cell membrane penetration and distribution in vivo. The polar surface area (TPSA) is 115.0600, indicating a certain polar group that helps form stable binding with target proteins. Its low water solubility (0.0986 mg/mL) limits its solubility in the aqueous phase, but its bioavailability can be improved through formulation techniques. The low permeability of the blood-brain barrier indicates that it mainly acts on peripheral tissues and reduces the risk of central nervous system side effects. The hERG channel inhibition test was negative, indicating a low risk of cardiotoxicity. The Ames test value was 1.8, indicating a low genotoxicity risk and a solid safety foundation.
3-Hydroxy-Bajiquinone is mainly found in Rubiaceae plants, especially in the roots and rhizomes of Morinda spp.. Traditional Chinese medicinal herbs such as Morinda officinalis are important natural sources of this compound. The content of 3-hydroxy-bathoquinone in plants is greatly affected by growth environment, harvest time, and processing method.
The extraction method mainly uses organic solvent extraction combined with chromatography separation technology. Common extraction solvents include ethanol, methanol, and their aqueous solutions, as they can effectively dissolve anthraquinone compounds. The extraction process generally includes crushing plant material, extraction extraction, filtration and concentration, liquid-liquid distribution, and column chromatography purification. High-performance liquid chromatography (HPLC) and mass spectrometry (MS) techniques are widely used for qualitative and quantitative analysis of 3-hydroxybaquiquinone in extracts. In addition, the application of ultrasound-assisted extraction and microwave-assisted extraction technologies has improved extraction efficiency and purity, reducing solvent usage and extraction time.
Pharmacological activity research on 3-hydroxy-barthoquinone mainly focuses on anti-osteoporosis, anti-inflammatory, antioxidant, and antitumor effects. Among these, its anti-osteoporosis effect is particularly prominent, involving multiple aspects of bone metabolism regulation.
The pathogenesis of osteoporosis is complex, involving an imbalance between bone formation and bone resorption. 3-Hydroxy-Thaliquinone regulates bone metabolism-related factors through multiple targets, promoting bone formation and inhibiting bone resorption, thereby improving bone density and strength. In vitro cell experiments have shown that 3-hydroxybaquiquinone can promote the proliferation and differentiation of osteoblasts (such as osteoblasts and osteoblasts), while inhibiting the differentiation and activity of osteoclasts. Animal model studies further confirmed its significant effects on bone density restoration and improvement of bone microstructure in osteoporosis rats.
The occurrence of osteoporosis is closely related to chronic inflammation and oxidative stress. 3-Hydroxybaquiquinone exhibits good anti-inflammatory activity, downregulating inflammatory factors such as TNF-α and IL-6, thereby reducing inflammatory damage to bone tissue. Its antioxidant capacity protects bone cells from oxidative damage by scavenging free radicals and enhancing endogenous antioxidant enzyme activity, further promoting bone metabolic balance.
Some studies have shown that 3-hydroxy-bathoquinone has certain antitumor activity, possibly by inducing tumor cell apoptosis and inhibiting proliferation. In addition, its protective effects on the cardiovascular and nervous systems are still in the early exploratory stage, but further research is needed.
The mechanism of action of 3-hydroxybaquiquinone in anti-osteoporosis involves multiple key molecular targets and signaling pathways, reflecting its multi-target and multi-pathway regulatory characteristics.
3-Hydroxy-Bahthoquinone achieves comprehensive regulation of osteocyte function by regulating signaling pathways such as Wnt/β-catenin, RANK/RANKL/OPG, MAPK, and NF-κB. It activates the Wnt/β-catenin pathway, promoting osteoblast differentiation and bone formation; Inhibits RANKL-mediated osteoclast activation and reduces bone resorption; At the same time, by suppressing NF-κB signaling, it reduces the release of inflammatory mediators and protects bone tissue from inflammatory damage.
3-Hydroxybathoquinone has a molecular weight of 286.2390, meeting the Lipinski rules for its medicinal chemical properties. A LogP value of 2.3375 indicates moderate lipid solubility, which is beneficial for cell membrane penetration. TPSA was 115.0600, indicating good polarity characteristics that facilitate binding to protein targets. Low water solubility (0.0986 mg/mL) may limit oral bioavailability, but can be improved through nanoformulations, solid dispersions, and other technologies. The blood-brain barrier has low permeability, reducing the risk of central nervous system side effects. No hERG channel suppression indicates a lower risk of cardiotoxicity. Ames trial results showed low genotoxicity risk and good safety.
Currently, systematic pharmacokinetic research on 3-hydroxy-baterinquinone is relatively limited. Preliminary in vivo experiments show that oral absorption is slow, and bioavailability is limited by solubility and first-pass effects. In vivo, distribution is mainly concentrated in bone tissue and the liver, with metabolism primarily carried out through hepatic enzyme systems, though metabolites are not yet fully understood. Excretion mainly involves kidneys and bile excretion. In the future, systematic pharmacokinetic and toxicological studies are needed to clarify its in vivo behavior and safe dosage range.
3-Hydroxy-Bajiquinone, as a natural anthraquinone compound, shows broad application potential in the field of osteoporosis treatment. Its multi-target mechanism regulating bone metabolism meets current osteoporosis treatment needs, especially suitable for long-term medication and preventive therapy. In the future, it can be used as a single active ingredient to develop new bone protection drugs or in combination with other drugs to enhance efficacy and reduce side effects.
In addition, the multiple pharmacological activities of 3-hydroxy-bathoquinone, including anti-inflammatory and antioxidant properties, provide a theoretical basis for its application in bone-related diseases such as osteoarthritis and rheumatoid arthritis. With advances in formulation technology, issues of water solubility and bioavailability are expected to be resolved, driving clinical translation.
Future research should focus on the following aspects:
1. Systematic pharmacokinetic and toxicological evaluation to ensure safety and effective dose range;
2. Structural optimization and derivatives design to enhance activity and drug properties;
3. Multicenter, large-sample clinical trials to verify efficacy and safety;
4. Research on combination drug mechanisms and explore synergistic effects with existing anti-osteoporosis drugs;
5. Develop novel formulations to improve oral bioavailability and patient compliance.
3-Hydroxy-Thaliquinone, as a natural anthraquinone compound with a unique structure and multiple biological activities, demonstrates significant pharmacological potential in combating osteoporosis and related bone metabolic diseases. By regulating multiple key targets and signaling pathways, it promotes bone formation and inhibits bone resorption, possessing anti-inflammatory and antioxidant effects, and has a solid foundation for druggability and safety. Although clinical research is still in its early stages, with ongoing improvements in pharmacokinetics, toxicology, and formulation technology, 3-hydroxybathoquinone is expected to become an important candidate for the next generation of natural bone protection drugs. Future multidisciplinary collaborative research will further reveal its mechanism of action, promote its clinical application, and bring new treatment options for osteoporosis patients.
Shenshuai
Wenjing
Hedandan
